secwatch / observer
8-K filed July 1, 2025, 7:59 PM ET ticker PRPH CIK 0000868278
regulatory confidence high sentiment positive materiality 0.65

ProPhase Labs, Inc. (PRPH): Nasdaq/NYSE listing notice — ProPhase Labs regains Nasdaq compliance after appointing new independent director

ProPhase Labs, Inc.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

ProPhase Labs, Inc. received a nasdaq deficiency notice notice regarding other (rules 5605(c)(2)(A), 5605(c)(4), 5605(c)(2), 5605).

Exchange
nasdaq
Notice
deficiency notice
Rules
5605(c)(2)(A), 5605(c)(4), 5605(c)(2), 5605
Exact text from the filing
mittee effective July 19, 2025, the day following the Company’s 2025 Annual Meeting. In response to the Company’s notification of Ms. Abenante’s appointment to the Board, on June 25, 2025, the Company received a letter from Nasdaq informing the Company that it was now in compliance with Nasdaq Rule 5605(c)(2) and that the matter is now closed. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements
View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ProPhase Labs, Inc. filing history →

Source: SEC EDGAR
accession 0001641172-25-017286
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.